BioSpaceOriginal article
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail
Phase 3MixedNegative
AI Analysis
Summary
Bausch + Lomb is advancing a dual-action dry eye disease drug to Phase 3 despite mixed Phase 2 results, where the candidate showed superiority at day 15 but failed to outperform active comparators at day 29.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to outperform active comparators at day 29 but showed significant superiority at day 15
Importance:6/10
Sentiment:
-0.30
dry eye diseasePhase 3dual-action eye dropsclinical trial
Related Companies
Read the original article
Published by BioSpace on August 25, 2026 11:57 AM